EUVIMEDEUVIMED entdecken
Open Access

Spironolactone use and oocyte maturation in patients undergoing controlled ovarian hyperstimulation

Atoosa Ghofranian, Samantha L Estevez, Bethany Dubois, Caroline Gellman, Dmitry Gounko, Joseph A Lee, Alan B Copperman, Kimberly Thornton

Journal of Assisted Reproduction and Genetics · 2024

DOI: 10.1007/s10815-024-03214-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Assisted Reproduction and Genetics, 2024. Verfasst von Atoosa Ghofranian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, Department of Obstetrics, Gynecology and Reproductive Science, New York, NY, USA. atoosagmd@gmail.com. Hauptthemen laut MEDLINE: Spironolactone, Ovulation Induction, Oocytes, Oocyte Retrieval. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the association between spironolactone use and controlled ovarian hyperstimulation (COH) outcomes. METHODS: Retrospective study, including patients who underwent COH. Oocyte yield and maturation rates were compared by categories of spironolactone use at the start of their cycle. RESULTS: 402 patients were included. 83 patients continued spironolactone, 44 patients discontinued spironolactone, and 275 matched control patients were spironolactone-naïve. No difference was observed in the number of oocytes retrieved (17 ± 14 vs. 15 ± 13, p = 0.4) or mature oocytes vitrified (15 ± 9.5 vs. 12 ± 11, p = 0.4) in patients who continued spironolactone use and spironolactone naïve patients, respectively. When comparing patients who continued spironolactone use and patients who discontinued spironolactone use, no difference was seen in the number of oocytes retrieved (17 ± 14 vs. 17.5 ± 7.8, p = 0.9) or mature oocytes vitrified (15 ± 9.5 vs. 13.5 ± 6.5, p = 0.5), respectively. There was no observed relationship between total daily spironolactone dose ( 200 mg/day) and the total number of mature oocytes vitrified (respectively, 14.0 ± 13.0, 16.0 ± 7.8, 14.0 ± 4.5, 11.0 ± 7.0 oocytes, p = 0.4). CONCLUSIONS: This is the first study to evaluate the association between spironolactone and oocyte yield and maturation rates during COH cycles. These findings can assist in counseling patients on the implications of continuing spironolactone during COH cycle.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SpironolactoneOvulation InductionOocytesOocyte RetrievalPregnancy RateHumansFemaleAdultPregnancyRetrospective StudiesFertilization in VitroIn Vitro Oocyte Maturation Techniques

Stichwörter der Autor:innen

AldactoneControlled ovarian hyperstimulationFertility preservationOocyte cryopreservationSpironolactone

Substanzen

Spironolactone

Autor:innen und Institutionen

  • Icahn School of Medicine at Mount Sinai, Department of Obstetrics, Gynecology and Reproductive Science, New York, NY, USA. atoosagmd@gmail.com.
  • Icahn School of Medicine at Mount Sinai, Department of Obstetrics, Gynecology and Reproductive Science, New York, NY, USA.
  • Reproductive Medicine Associates of New York, 635 Madison Avenue, 11th Floor, New York, NY, 10022, USA.

Förderung

  • NCATS NIH HHS

Zitieren

APA

Ghofranian, A., Estevez, S. L., Dubois, B., Gellman, C., Gounko, D., Lee, J. A., Copperman, A. B., & Thornton, K. (2024). Spironolactone use and oocyte maturation in patients undergoing controlled ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics. https://doi.org/10.1007/s10815-024-03214-6

Vancouver

Ghofranian A, Estevez SL, Dubois B, Gellman C, Gounko D, Lee JA, et al. Spironolactone use and oocyte maturation in patients undergoing controlled ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics. 2024. doi:10.1007/s10815-024-03214-6

BibTeX
@article{Ghofranian2024,
  author = {Ghofranian, Atoosa and Estevez, Samantha L and Dubois, Bethany and Gellman, Caroline and Gounko, Dmitry and Lee, Joseph A and Copperman, Alan B and Thornton, Kimberly},
  title = {Spironolactone use and oocyte maturation in patients undergoing controlled ovarian hyperstimulation},
  journal = {Journal of Assisted Reproduction and Genetics},
  year = {2024},
  doi = {10.1007/s10815-024-03214-6}
}
Kostenlos starten →